CoChat
Sign Up
Cited by 192Autoimmune Neurological Disorders and TreatmentsInfectious Encephalopathies and EncephalitisPeripheral Neuropathies and Disorders

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis

Open access
Probasco, John C., Solnes, Lilja, Nalluri, Abhinav, Cohen, Jesse, Jones, Krystyna M., Zan, Elcin, Javadi, Mehrbod S., Venkatesan, Arun·2017·Neurology Neuroimmunology & Neuroinflammation
DOI 10.1212/nxi.0000000000000352PMC PMC5442608
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective: To compare the rate of abnormal brain metabolism by FDG-PET/CT to other paraclinical findings and to describe brain metabolism patterns in autoimmune encephalitis (AE). Methods: A retrospective review of clinical data and initial dedicated brain FDG-PET/CT studies for neurology inpatients with AE, per consensus criteria, treated at a single tertiary center over 123 months. Z-score maps of FDG-PET/CT were made using 3-dimensional stereotactic surface projections with comparison to age group–matched controls. Brain region mean Z-scores with magnitudes ≥2.00 were interpreted as significant. Comparisons were made to rates of abnormal initial brain MRI, abnormal initial EEG, and presence of intrathecal inflammation. Results: Sixty-one patients with AE (32 seropositive) underwent brain FDG-PET/CT at median 4 weeks of symptoms (interquartile range [IQR] 9 weeks) and median 4 days from MRI (IQR 8.5 days). FDG-PET/CT was abnormal in 52 (85%) patients, with 42 (69%) demonstrating only hypometabolism. Isolated hypermetabolism was demonstrated in 2 (3%) patients. Both hypermetabolic and hypometabolic brain regions were noted in 8 (13%) patients. Nine (15%) patients had normal FDG-PET/CT studies. CSF inflammation was evident in 34/55 (62%) patients, whereas initial EEG (17/56, 30%) and MRI (23/57, 40%) were abnormal in fewer. Detection of 2 or more of these paraclinical findings was in weak agreement with abnormal brain FDG-PET/CT (κ = 0.16, p = 0.02). Conclusions: FDG-PET/CT was more often abnormal than initial EEG, MRI, and CSF studies in neurology inpatients with AE, with brain region hypometabolism the most frequently observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/nxi.0000000000000352

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Antibody status of patients with AE Antibody status of patients with AE who underwent dedicated brain FDG-PET/CT (N = 61). AE = autoimmune encephalitis; ANNA-1 = anti–neuronal nuclear antibody 1; CRMP5 = collapsin response mediator protein 5; GAD65 = 65 kDa glutamic acid decarboxylase enzyme; VGKCc = voltage-gated potassium channel-complex antibodies different from leucine-rich inactivated 1 protein (LGI1) and contactin-associated protein-2 (CASPR2); AChR = acetylcholine receptor antibody.
Figure 1 Antibody status of patients with AE Antibody status of patients with AE who underwent dedicated brain FDG-PET/CT (N = 61). AE = autoimmune encephalitis; ANNA-1 = anti–neuronal nuclear antibody 1; CRMP5 = collapsin response mediator protein 5; GAD65 = 65 kDa glutamic acid decarboxylase enzyme; VGKCc = voltage-gated potassium channel-complex antibodies different from leucine-rich inactivated 1 protein (LGI1) and contactin-associated protein-2 (CASPR2); AChR = acetylcholine receptor antibody.CC BY-NC-ND · PubMed Central
Figure 2 Metabolism across brain regions in AE Boxplots of Z-scores for FDG-avidity for brain areas on dedicated FDG-PET/CT for (A) patients meeting consensus criteria for AE, (B) seronegative and seropositive patients meeting the consensus criteria for AE. Z-scores varied across brain regions for patients with AE (p < 0.005), with values for the caudate being greater than those for frontal (p < 0.005), temporal (p = 0.002), parietal (p < 0.005), and occipital (p < 0.005) lobes. No difference was noted between seronegative and seropositive patient groups (p = 0.08). AE = autoimmune encephalitis.
Figure 2 Metabolism across brain regions in AE Boxplots of Z-scores for FDG-avidity for brain areas on dedicated FDG-PET/CT for (A) patients meeting consensus criteria for AE, (B) seronegative and seropositive patients meeting the consensus criteria for AE. Z-scores varied across brain regions for patients with AE (p < 0.005), with values for the caudate being greater than those for frontal (p < 0.005), temporal (p = 0.002), parietal (p < 0.005), and occipital (p < 0.005) lobes. No difference was noted between seronegative and seropositive patient groups (p = 0.08). AE = autoimmune encephalitis.CC BY-NC-ND · PubMed Central
Figure 3 Brain MRI, brain FDG-PET/CT and hypometabolic 3D-SSP maps for 3 patients with AE Brain MRI, brain FDG-PET/CT, and hypometabolic 3D-SSP maps, respectively, for patients with anti-NMDAR encephalitis (A–C), anti-LGI1 encephalitis (D–F), and seronegative AE (G–I). For the anti-NMDAR encephalitis patient, note normal T2/FLAIR MRI (A) with right basal ganglia, right frontotemporoparietal, left frontal, and bilateral posterior cortical hypometabolism centered on the middle occipital lobe on FDG-PET/CT and 3D-SSP maps (B and C). For the anti-LGI1 patient, note normal T2/FLAIR MRI (D) with relatively normal basal ganglia metabolism (E) in setting of diffuse frontotemporoparietal hypometabolism on FDG-PET/CT and 3D-SSP maps (E and F). For the seronegative AE patient, again note normal T2/FLAIR MRI (G) with diffuse frontotemporoparietal hypometabolism on FDG-PET/CT and 3D-SSP maps (H and I). A = anterior; AE = autoimmune encephalitis; L = left; LGI1 = leucine-rich inactivated 1 protein; NMDAR = NMDA receptor; P = posterior; R = right; and 3D-SSP, 3-dimensional stereotactic surface projection.
Figure 3 Brain MRI, brain FDG-PET/CT and hypometabolic 3D-SSP maps for 3 patients with AE Brain MRI, brain FDG-PET/CT, and hypometabolic 3D-SSP maps, respectively, for patients with anti-NMDAR encephalitis (A–C), anti-LGI1 encephalitis (D–F), and seronegative AE (G–I). For the anti-NMDAR encephalitis patient, note normal T2/FLAIR MRI (A) with right basal ganglia, right frontotemporoparietal, left frontal, and bilateral posterior cortical hypometabolism centered on the middle occipital lobe on FDG-PET/CT and 3D-SSP maps (B and C). For the anti-LGI1 patient, note normal T2/FLAIR MRI (D) with relatively normal basal ganglia metabolism (E) in setting of diffuse frontotemporoparietal hypometabolism on FDG-PET/CT and 3D-SSP maps (E and F). For the seronegative AE patient, again note normal T2/FLAIR MRI (G) with diffuse frontotemporoparietal hypometabolism on FDG-PET/CT and 3D-SSP maps (H and I). A = anterior; AE = autoimmune encephalitis; L = left; LGI1 = leucine-rich inactivated 1 protein; NMDAR = NMDA receptor; P = posterior; R = right; and 3D-SSP, 3-dimensional stereotactic surface projection.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 30

  1. 10.1016/S1474-4422(15)00401-9 · DOI
  2. 10.1093/brain/awh526 · DOI
  3. 10.1097/RLU.0b013e31824852c7 · DOI
  4. 10.1007/s00415-013-7048-2 · DOI
  5. 10.1097/MNM.0000000000000163 · DOI
  6. 10.1016/j.neurol.2012.05.014 · DOI
  7. 10.1016/S1474-4422(16)30140-5 · DOI
  8. 10.1136/jnnp-2011-301969 · DOI
  9. 10.1186/1471-2377-14-136 · DOI
  10. 10.1016/j.braindev.2015.10.013 · DOI
  11. 10.1097/RLU.0000000000001164 · DOI
  12. 10.1016/j.jneuroim.2016.03.012 · DOI
  13. 10.1097/00003072-200410000-00004 · DOI
  14. 10.1016/j.jneuroim.2014.02.011 · DOI
  15. 10.1016/j.jneuroim.2013.10.005 · DOI
  16. Newey CR, Sarwal A, Hantus S. [(18)F]-Fluoro-deoxy-glucose positron emission tomography scan should be obtained early in cases of autoimmune encephalitis. Autoimmune Dis 2016;2016:9450452.
  17. 10.14581/jer.14014 · DOI
  18. 10.1016/j.jneuroim.2016.05.016 · DOI
  19. 10.3171/jns.1995.83.4.0657 · DOI
  20. 10.1111/j.1528-1157.2000.tb00213.x · DOI
  21. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–1248.
  22. 10.1093/brain/aws032 · DOI
  23. 10.1016/S1474-4422(10)70253-2 · DOI
  24. 10.1016/S1474-4422(16)30130-2 · DOI
  25. 10.2967/jnmt.108.059584 · DOI
  26. 10.1001/archneurol.2009.336 · DOI
  27. 10.4065/mcp.2010.0326 · DOI
  28. 10.1093/brain/awm177 · DOI · Paper page
  29. 10.1097/RLU.0b013e318170d4e0 · DOI
  30. 10.1097/RLU.0b013e31824c5e2f · DOI

Cited by

Sorted by citations

Metadata

Authors
Probasco, J. C., Solnes, L., Nalluri, A., Cohen, J., Jones, K. M., Zan, E., Javadi, M. S., & Venkatesan, A.
Affiliations
  • Johns Hopkins University (US)
  • From the Department of Neurology (J.C.P., A.N., J.C., A.V.), Johns Hopkins Encephalitis Center, Department of Neurology (J.C.P.), Johns Hopkins Center for Refractory Status Epilepticus and Neuroinflammation, and Russell H. Morgan Department of Radiology and Radiological Sciences (L.S., K.M.J., E.Z., M.S.J.), Johns Hopkins University School of Medicine, Baltimore, MD.
Corresponding author
Probasco, John C.
ORCID
Venue
Neurology Neuroimmunology & Neuroinflammation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2017-07
Volume
4
Issue
4
Pages
e352-e352
ISSN
2332-7812 (ISSN-L)
DOI
10.1212/nxi.0000000000000352
PMC
PMC5442608
OpenAlex
W2613762122
Cited by
192
References
1
Citations by year
2026: 12 · 2025: 16 · 2024: 15 · 2023: 27 · 2022: 23 · 2021: 39 · 2020: 22 · 2019: 21 · 2018: 10 · 2017: 6
FWCI
11.24
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Neurology Neuroimmunology & Neuroinflammation (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
  • Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
  • Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
Keywords
autoimmune encephalitis, FDG PET/CT, brain metabolism, hypometabolism, hypermetabolism, intrathecal inflammation, cerebrospinal fluid inflammation, brain MRI, EEG abnormalities, early diagnosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review